Page last updated: 2024-11-08

dn 108

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

DN 108: RN & structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID183791
SCHEMBL ID305687
MeSH IDM0294709

Synonyms (15)

Synonym
dn 108
n-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenyl]-1-phenylcyclopropane-1-carboxamide
195604-21-8
dn-108
5-(4-(1-phenyl-1-cyclopropanecarbonylamino)benzyl)thiazolidine-2,4-dione
0m650i7781 ,
thiazolidine-2,4-dione, 5-(4-(1-phenyl-1-cyclopropanecarbonylamino)benzyl)-
unii-0m650i7781
SCHEMBL305687
cyclopropanecarboxamide, n-(4-((2,4-dioxo-5-thiazolidinyl)methyl)phenyl)-1-phenyl-
FTRMOJIRMFXZJV-UHFFFAOYSA-N
n-{4-[(4-hydroxy-2-oxo-2,5-dihydro-1,3-thiazol-5-yl)methyl]phenyl}-1-phenylcyclopropane-1-carboxamide
DTXSID40941342
Q27236957
PD161045

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacological and pharmacokinetic studies of DN-108 were done."( Pharmacological and pharmacokinetic studies of the newly synthesized thiazolidinedione derivative 5-(4-(1-phenyl-1-cyclopropanecarbonylamino)benzyl)-thiazolidine-2 ,4-dio ne.
Hayashibe, M; Ino, Y; Kurumi, M; Matsuzaki, Y; Muta, Y; Nomura, Y; Suzuki, S; Ueda, N, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's5 (71.43)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.69 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index29.80 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]